{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:21:08Z","timestamp":1771629668016,"version":"3.50.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11910-025-01425-7","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T03:06:30Z","timestamp":1748055990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases"],"prefix":"10.1007","volume":"25","author":[{"given":"Bayan","family":"Moustafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Trifan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"1425_CR1","unstructured":"National Diabetes Statistics Report Centers for Disease Control. and Prevention2024 [Available from: https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html"},{"issue":"3","key":"1425_CR2","doi-asserted-by":"publisher","first-page":"Itc33","DOI":"10.7326\/AITC202203150","volume":"175","author":"FZ Syed","year":"2022","unstructured":"Syed FZ. Type 1 diabetes mellitus. Ann Intern Med. 2022;175(3):Itc33\u201348.","journal-title":"Ann Intern Med"},{"key":"1425_CR3","doi-asserted-by":"crossref","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17).","DOI":"10.3390\/ijms21176275"},{"issue":"8","key":"1425_CR4","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","volume":"149","author":"SS Martin","year":"2024","unstructured":"Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 heart disease and stroke statistics: A report of US and global data from the American heart association. Circulation. 2024;149(8):e347\u2013913.","journal-title":"Circulation"},{"issue":"11","key":"1425_CR5","doi-asserted-by":"publisher","first-page":"e053698","DOI":"10.1136\/bmjopen-2021-053698","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Li J, Dou Y, Ma H. Impacts of type 2 diabetes mellitus and hypertension on the incidence of cardiovascular diseases and stroke in China real-world setting: a retrospective cohort study. BMJ Open. 2021;11(11):e053698.","journal-title":"BMJ Open"},{"issue":"10","key":"1425_CR6","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00125-006-0378-1","volume":"49","author":"G Hu","year":"2006","unstructured":"Hu G, Jousilahti P, Sarti C, Antikainen R, Tuomilehto J. The effect of diabetes and stroke at baseline and during follow-up on stroke mortality. Diabetologia. 2006;49(10):2309\u201316.","journal-title":"Diabetologia"},{"key":"1425_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7812\/TPP\/18-034","volume":"22","author":"R Madievsky","year":"2018","unstructured":"Madievsky R. Spotlight on antidiabetic agents with cardiovascular or renoprotective benefits. Perm J. 2018;22:18\u2013034.","journal-title":"Perm J"},{"issue":"4","key":"1425_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.amjms.2016.01.011","volume":"351","author":"R Chen","year":"2016","unstructured":"Chen R, Ovbiagele B, Feng W. Diabetes and stroke: epidemiology, pathophysiology, pharmaceuticals and outcomes. Am J Med Sci. 2016;351(4):380\u20136.","journal-title":"Am J Med Sci"},{"issue":"9733","key":"1425_CR9","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215\u201322.","journal-title":"Lancet"},{"issue":"6","key":"1425_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1161\/STROKEAHA.113.001318","volume":"44","author":"JC Khoury","year":"2013","unstructured":"Khoury JC, Kleindorfer D, Alwell K, Moomaw CJ, Woo D, Adeoye O, et al. Diabetes mellitus: a risk factor for ischemic stroke in a large biracial population. Stroke. 2013;44(6):1500\u20134.","journal-title":"Stroke"},{"issue":"3","key":"1425_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/jdi.12932","volume":"10","author":"LH Lau","year":"2019","unstructured":"Lau LH, Lew J, Borschmann K, Thijs V, Ekinci EI. Prevalence of diabetes and its effects on stroke outcomes: A meta-analysis and literature review. J Diabetes Investig. 2019;10(3):780\u201392.","journal-title":"J Diabetes Investig"},{"key":"1425_CR12","doi-asserted-by":"publisher","first-page":"e3564","DOI":"10.1136\/bmj.e3564","volume":"344","author":"M Lee","year":"2012","unstructured":"Lee M, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B. Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ. 2012;344:e3564.","journal-title":"BMJ"},{"key":"1425_CR13","doi-asserted-by":"crossref","unstructured":"Mitsios JP, Ekinci EI, Mitsios GP, Churilov L, Thijs V. Relationship between glycated hemoglobin and stroke risk: A systematic review and Meta-Analysis. J Am Heart Assoc. 2018;7(11).","DOI":"10.1161\/JAHA.117.007858"},{"issue":"6","key":"1425_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1159\/000519327","volume":"55","author":"L Zhang","year":"2021","unstructured":"Zhang L, Li X, Wolfe CDA, O\u2019Connell MDL, Wang Y. Diabetes as an independent risk factor for stroke recurrence in ischemic stroke patients: an updated Meta-Analysis. Neuroepidemiology. 2021;55(6):427\u201335.","journal-title":"Neuroepidemiology"},{"key":"1425_CR15","doi-asserted-by":"publisher","first-page":"983723","DOI":"10.3389\/fendo.2022.983723","volume":"13","author":"L Mao","year":"2022","unstructured":"Mao L, Yin R, Yang L, Zhao D. Role of advanced glycation end products on vascular smooth muscle cells under diabetic atherosclerosis. Front Endocrinol (Lausanne). 2022;13:983723.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"31","key":"1425_CR16","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1093\/eurheartj\/eht149","volume":"34","author":"F Paneni","year":"2013","unstructured":"Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34(31):2436\u201343.","journal-title":"Eur Heart J"},{"key":"1425_CR17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3389\/fphar.2017.00798","volume":"8","author":"SV Suryavanshi","year":"2017","unstructured":"Suryavanshi SV, Kulkarni YA. NF-\u03ba\u03b2: A potential target in the management of vascular complications of diabetes. Front Pharmacol. 2017;8:798.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1425_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.metabol.2004.09.014","volume":"54","author":"N Yoshida","year":"2005","unstructured":"Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism. 2005;54(3):345\u201350.","journal-title":"Metabolism"},{"issue":"11","key":"1425_CR19","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1161\/STROKEAHA.123.042512","volume":"54","author":"T Miyagi","year":"2023","unstructured":"Miyagi T, Ishida A, Shinzato T, Ohya Y. Arterial stiffness is associated with small vessel disease irrespective of blood pressure in Stroke-Free individuals. Stroke. 2023;54(11):2814\u201321.","journal-title":"Stroke"},{"issue":"7","key":"1425_CR20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S1474-4422(19)30079-1","volume":"18","author":"JM Wardlaw","year":"2019","unstructured":"Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684\u201396.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1425_CR21","doi-asserted-by":"publisher","first-page":"107605","DOI":"10.1016\/j.jdiacomp.2020.107605","volume":"34","author":"A Fujiyoshi","year":"2020","unstructured":"Fujiyoshi A, Suri MFK, Alonso A, Selvin E, Chu H, Guallar E, et al. Hyperglycemia, duration of diabetes, and intracranial atherosclerotic stenosis by magnetic resonance angiography: the ARIC-NCS study. J Diabetes Complications. 2020;34(9):107605.","journal-title":"J Diabetes Complications"},{"issue":"1","key":"1425_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1161\/01.STR.26.1.14","volume":"26","author":"RL Sacco","year":"1995","unstructured":"Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan stroke study. Stroke. 1995;26(1):14\u201320.","journal-title":"Stroke"},{"issue":"1","key":"1425_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1212\/01.WNL.0000132637.30287.B4","volume":"63","author":"JF Arenillas","year":"2004","unstructured":"Arenillas JF, Molina CA, Chac\u00f3n P, Rovira A, Montaner J, Coscojuela P, et al. High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology. 2004;63(1):27\u201332.","journal-title":"Neurology"},{"issue":"1","key":"1425_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3174\/ajnr.A6878","volume":"42","author":"S Jiao","year":"2021","unstructured":"Jiao S, Huang J, Chen Y, Song Y, Gong T, Lu J, et al. Impacts of glycemic control on intracranial plaque in patients with type 2 diabetes mellitus: A vessel wall MRI study. AJNR Am J Neuroradiol. 2021;42(1):75\u201381.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"1425_CR25","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","volume":"27","author":"RM Krauss","year":"2004","unstructured":"Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496\u2013504.","journal-title":"Diabetes Care"},{"issue":"1","key":"1425_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.amjcard.2011.03.004","volume":"108","author":"RR Huxley","year":"2011","unstructured":"Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108(1):56\u201362.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1425_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-019-0983-1","volume":"19","author":"S Seyed Ahmadi","year":"2020","unstructured":"Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19(1):9.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1425_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-017-0604-9","volume":"16","author":"BS Karam","year":"2017","unstructured":"Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017;16(1):120.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1425_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/14779072.2023.2160319","volume":"21","author":"SE Choi","year":"2023","unstructured":"Choi SE, Sagris D, Hill A, Lip GYH, Abdul-Rahim AH. Atrial fibrillation and stroke. Expert Rev Cardiovasc Ther. 2023;21(1):35\u201356.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4","key":"1425_CR30","doi-asserted-by":"publisher","first-page":"e023643","DOI":"10.1161\/JAHA.121.023643","volume":"11","author":"H Abdel-Qadir","year":"2022","unstructured":"Abdel-Qadir H, Gunn M, Lega IC, Pang A, Austin PC, Singh SM, et al. Association of diabetes duration and glycemic control with stroke rate in patients with atrial fibrillation and diabetes: A Population-Based cohort study. J Am Heart Assoc. 2022;11(4):e023643.","journal-title":"J Am Heart Assoc"},{"key":"1425_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.amjcard.2020.06.049","volume":"131","author":"SH Patlolla","year":"2020","unstructured":"Patlolla SH, Lee HC, Noseworthy PA, Wysokinski WE, Hodge DO, Greene EL, et al. Impact of diabetes mellitus on stroke and survival in patients with atrial fibrillation. Am J Cardiol. 2020;131:33\u20139.","journal-title":"Am J Cardiol"},{"issue":"14","key":"1425_CR32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386.","journal-title":"N Engl J Med"},{"issue":"15","key":"1425_CR33","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"24","key":"1425_CR34","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, Buse JB, et al. Effects of intensive glucose Lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"issue":"24","key":"1425_CR35","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372.","journal-title":"N Engl J Med"},{"issue":"Supplement1","key":"1425_CR36","first-page":"S181","volume":"48","author":"9","year":"2025","unstructured":"9. Pharmacologic approaches to glycemic treatment: standards of care in Diabetes-2025. Diabetes Care. 2025;48(Supplement1):S181\u2013206.","journal-title":"Diabetes Care"},{"issue":"2","key":"1425_CR37","doi-asserted-by":"publisher","first-page":"102721","DOI":"10.1016\/j.dsx.2023.102721","volume":"17","author":"P Paridari","year":"2023","unstructured":"Paridari P, Jabermoradi S, Gholamzadeh R, Vazifekhah S, Vazirizadeh-Mahabadi M, Roshdi Dizaji S, et al. Can Metformin use reduce the risk of stroke in diabetic patients? A systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17(2):102721.","journal-title":"Diabetes Metab Syndr"},{"key":"1425_CR38","doi-asserted-by":"publisher","first-page":"172984","DOI":"10.1016\/j.ejphar.2020.172984","volume":"872","author":"M Markowicz-Piasecka","year":"2020","unstructured":"Markowicz-Piasecka M, Sadkowska A, Huttunen KM, Podsiedlik M, Mikiciuk-Olasik E, Sikora J. An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis. Eur J Pharmacol. 2020;872:172984.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1425_CR39","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.09.001","volume":"23","author":"YY Cheng","year":"2014","unstructured":"Cheng YY, Leu HB, Chen TJ, Chen CL, Kuo CH, Lee SD, et al. Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. J Stroke Cerebrovasc Dis. 2014;23(2):e99\u2013105.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"14","key":"1425_CR40","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"1425_CR41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","volume":"48","author":"M Lee","year":"2017","unstructured":"Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B. Pioglitazone for secondary stroke prevention: A systematic review and Meta-Analysis. Stroke. 2017;48(2):388\u201393.","journal-title":"Stroke"},{"issue":"Suppl 2","key":"1425_CR42","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.2337\/dcS13-2031","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, Currie CJ, Schernthaner GH. Do we still need Pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013;36(Suppl 2):S155\u201361.","journal-title":"Diabetes Care"},{"issue":"12","key":"1425_CR43","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"1","key":"1425_CR44","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"1425_CR45","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1425_CR46","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"key":"1425_CR47","doi-asserted-by":"publisher","first-page":"106448","DOI":"10.1016\/j.phrs.2022.106448","volume":"184","author":"R Marfella","year":"2022","unstructured":"Marfella R, Scisciola L, D\u2019Onofrio N, Maiello C, Trotta MC, Sardu C, et al. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacol Res. 2022;184:106448.","journal-title":"Pharmacol Res"},{"issue":"4","key":"1425_CR48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00795-022-00334-9","volume":"55","author":"D Nakano","year":"2022","unstructured":"Nakano D, Akiba J, Tsutsumi T, Kawaguchi M, Yoshida T, Koga H, et al. Hepatic expression of sodium-glucose cotransporter 2 (SGLT2) in patients with chronic liver disease. Med Mol Morphol. 2022;55(4):304\u201315.","journal-title":"Med Mol Morphol"},{"issue":"11","key":"1425_CR49","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/eurheartj\/ehab765","volume":"43","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. SGLT2 inhibitors: the Statins of the 21st century. Eur Heart J. 2022;43(11):1029\u201330.","journal-title":"Eur Heart J"},{"issue":"12","key":"1425_CR50","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","volume":"54","author":"H Rahmoune","year":"2005","unstructured":"Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427\u201334.","journal-title":"Diabetes"},{"issue":"1","key":"1425_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33\u201359.","journal-title":"Drugs"},{"key":"1425_CR52","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12933-015-0297-x","volume":"14","author":"P Fioretto","year":"2015","unstructured":"Fioretto P, Giaccari A, Sesti G. Efficacy and safety of Dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015;14:142.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1425_CR53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"MA Abdul-Ghani","year":"2011","unstructured":"Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515\u201331.","journal-title":"Endocr Rev"},{"issue":"10","key":"1425_CR54","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"14","key":"1425_CR55","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s40265-017-0801-6","volume":"77","author":"ED Deeks","year":"2017","unstructured":"Deeks ED, Scheen AJ, Canagliflozin. A review in type 2 diabetes. Drugs. 2017;77(14):1577\u201392.","journal-title":"Drugs"},{"issue":"10","key":"1425_CR56","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s40265-018-0937-z","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE, Empagliflozin. A review in type 2 diabetes. Drugs. 2018;78(10):1037\u201348.","journal-title":"Drugs"},{"issue":"2","key":"1425_CR57","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2337\/cd18-0097","volume":"37","author":"VK Nguyen","year":"2019","unstructured":"Nguyen VK, White JR. Jr. Overview of Ertugliflozin. Clin Diabetes. 2019;37(2):176\u20138.","journal-title":"Clin Diabetes"},{"issue":"30","key":"1425_CR58","doi-asserted-by":"publisher","first-page":"e16575","DOI":"10.1097\/MD.0000000000016575","volume":"98","author":"M Feng","year":"2019","unstructured":"Feng M, Lv H, Xu X, Wang J, Lyu W, Fu S. Efficacy and safety of Dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Med (Baltim). 2019;98(30):e16575.","journal-title":"Med (Baltim)"},{"issue":"1","key":"1425_CR59","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12933-021-01352-0","volume":"20","author":"A Tanaka","year":"2021","unstructured":"Tanaka A, Shimabukuro M, Teragawa H, Okada Y, Takamura T, Taguchi I, et al. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline Metformin. Cardiovasc Diabetol. 2021;20(1):160.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"1425_CR60","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1016\/j.clinthera.2017.10.003","volume":"39","author":"JF Yale","year":"2017","unstructured":"Yale JF, Xie J, Sherman SE, Garceau C. Canagliflozin in conjunction with sulfonylurea maintains glycemic control and weight loss over 52 weeks: A randomized, controlled trial in patients with type 2 diabetes mellitus. Clin Ther. 2017;39(11):2230\u2013e422.","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"1425_CR61","first-page":"S125","volume":"45","author":"9","year":"2022","unstructured":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125\u201343.","journal-title":"Diabetes Care"},{"issue":"24","key":"1425_CR62","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1425_CR63","doi-asserted-by":"publisher","first-page":"664181","DOI":"10.3389\/fphar.2021.664181","volume":"12","author":"C Ren","year":"2021","unstructured":"Ren C, Sun K, Zhang Y, Hu Y, Hu B, Zhao J, et al. Sodium-Glucose CoTransporter-2 inhibitor empagliflozin ameliorates Sunitinib-Induced cardiac dysfunction via regulation of AMPK-mTOR signaling Pathway-Mediated autophagy. Front Pharmacol. 2021;12:664181.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1425_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41420-021-00801-9","volume":"8","author":"CH Park","year":"2022","unstructured":"Park CH, Lee B, Han M, Rhee WJ, Kwak MS, Yoo TH, et al. Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells. Cell Death Discov. 2022;8(1):12.","journal-title":"Cell Death Discov"},{"key":"1425_CR65","doi-asserted-by":"publisher","first-page":"101337","DOI":"10.1016\/j.molmet.2021.101337","volume":"54","author":"N D\u2019Onofrio","year":"2021","unstructured":"D\u2019Onofrio N, Sardu C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, et al. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment. Mol Metab. 2021;54:101337.","journal-title":"Mol Metab"},{"issue":"1","key":"1425_CR66","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41419-022-05542-w","volume":"14","author":"D Smirnov","year":"2023","unstructured":"Smirnov D, Eremenko E, Stein D, Kaluski S, Jasinska W, Cosentino C, et al. SIRT6 is a key regulator of mitochondrial function in the brain. Cell Death Dis. 2023;14(1):35.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1425_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12933-019-0807-3","volume":"18","author":"Y Li","year":"2019","unstructured":"Li Y, Liu B, Li Y, Jing X, Deng S, Yan Y, et al. Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019;18(1):3.","journal-title":"Cardiovasc Diabetol"},{"key":"1425_CR68","doi-asserted-by":"publisher","first-page":"106322","DOI":"10.1016\/j.ejps.2022.106322","volume":"180","author":"H Yaribeygi","year":"2023","unstructured":"Yaribeygi H, Maleki M, Butler AE, Jamialahmadi T, Sahebkar A. Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity. Eur J Pharm Sci. 2023;180:106322.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1425_CR69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Q Shao","year":"2019","unstructured":"Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019;18(1):165.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1425_CR70","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.ekir.2024.02.1435","volume":"9","author":"SA Lee","year":"2024","unstructured":"Lee SA, Riella LV. Narrative review of Immunomodulatory and Anti-inflammatory effects of Sodium-Glucose cotransporter 2 inhibitors: unveiling novel therapeutic frontiers. Kidney Int Rep. 2024;9(6):1601\u201313.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"1425_CR71","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","volume":"12","author":"C Hierro-Bujalance","year":"2020","unstructured":"Hierro-Bujalance C, Infante-Garcia C, Del Marco A, Herrera M, Carranza-Naval MJ, Suarez J, et al. Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes. Alzheimers Res Ther. 2020;12(1):40.","journal-title":"Alzheimers Res Ther"},{"issue":"22","key":"1425_CR72","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"5","key":"1425_CR73","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018;138(5):458\u201368.","journal-title":"Circulation"},{"issue":"7","key":"1425_CR74","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1425_CR75","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"15","key":"1425_CR76","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with Ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"key":"1425_CR77","doi-asserted-by":"crossref","unstructured":"Pescariu SA, Elagez A, Nallapati B, Bratosin F, Bucur A, Negru A et al. Examining the impact of Ertugliflozin on cardiovascular outcomes in patients with diabetes and metabolic syndrome: A systematic review of clinical trials. Pharmaceuticals (Basel). 2024;17(7).","DOI":"10.3390\/ph17070929"},{"issue":"2","key":"1425_CR78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"3","key":"1425_CR79","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374.","journal-title":"Nat Med"},{"issue":"15","key":"1425_CR80","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"5","key":"1425_CR81","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/dom.12244","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(5):457\u201366.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1425_CR82","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s13300-021-01104-z","volume":"12","author":"A Jane\u017e","year":"2021","unstructured":"Jane\u017e A, Fioretto P. SGLT2 inhibitors and the clinical implications of associated weight loss in type 2 diabetes: A narrative review. Diabetes Ther. 2021;12(8):2249\u201361.","journal-title":"Diabetes Ther"},{"key":"1425_CR83","doi-asserted-by":"crossref","unstructured":"Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2).","DOI":"10.3390\/metabo11020087"},{"issue":"9896","key":"1425_CR84","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of Canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with Metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941\u201350.","journal-title":"Lancet"},{"issue":"12","key":"1425_CR85","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/dom.12185","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, et al. Efficacy and safety of Empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to Metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15(12):1154\u201360.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1425_CR86","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1185\/03007995.2014.890925","volume":"30","author":"P Nyirjesy","year":"2014","unstructured":"Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, et al. Genital mycotic infections with Canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30(6):1109\u201319.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1425_CR87","doi-asserted-by":"publisher","first-page":"e027764","DOI":"10.1161\/JAHA.122.027764","volume":"12","author":"SN Chang","year":"2023","unstructured":"Chang SN, Chen JJ, Huang PS, Wu CK, Wang YC, Hwang JJ, et al. Sodium-Glucose Cotransporter-2 inhibitor prevents stroke in patients with diabetes and atrial fibrillation. J Am Heart Assoc. 2023;12(10):e027764.","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"1425_CR88","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of Dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation. 2020;141(15):1227\u201334.","journal-title":"Circulation"},{"key":"1425_CR89","doi-asserted-by":"publisher","first-page":"105836","DOI":"10.1016\/j.phrs.2021.105836","volume":"172","author":"A Mascolo","year":"2021","unstructured":"Mascolo A, Scavone C, Scisciola L, Chiodini P, Capuano A, Paolisso G. SGLT-2 inhibitors reduce the risk of cerebrovascular\/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies. Pharmacol Res. 2021;172:105836.","journal-title":"Pharmacol Res"},{"issue":"23","key":"1425_CR90","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","volume":"149","author":"SM Patel","year":"2024","unstructured":"Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, et al. Sodium-Glucose Cotransporter-2 inhibitors and major adverse cardiovascular outcomes: A SMART-C collaborative Meta-Analysis. Circulation. 2024;149(23):1789\u2013801.","journal-title":"Circulation"},{"issue":"5","key":"1425_CR91","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","volume":"52","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, et al. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and Meta-Analysis. Stroke. 2021;52(5):1545\u201356.","journal-title":"Stroke"},{"issue":"8","key":"1425_CR92","doi-asserted-by":"publisher","first-page":"107730","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107730","volume":"33","author":"E Pasqualotto","year":"2024","unstructured":"Pasqualotto E, Rodrigues FR, de Oliveira Almeida GBESR, Kabariti G, Ferreira JC. The effect of sodium-glucose transporter 2 inhibitors on stroke in patients with type 2 diabetes: A meta-analysis. J Stroke Cerebrovasc Dis. 2024;33(8):107730.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"3","key":"1425_CR93","doi-asserted-by":"publisher","first-page":"e014908","DOI":"10.1161\/JAHA.119.014908","volume":"9","author":"C Arnott","year":"2020","unstructured":"Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, et al. Sodium-Glucose cotransporter 2 Inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: A systematic review and Meta-Analysis. J Am Heart Assoc. 2020;9(3):e014908.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1425_CR94","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1425_CR95","doi-asserted-by":"publisher","first-page":"100944","DOI":"10.1016\/j.arr.2019.100944","volume":"55","author":"M Xue","year":"2019","unstructured":"Xue M, Xu W, Ou YN, Cao XP, Tan MS, Tan L, et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev. 2019;55:100944.","journal-title":"Ageing Res Rev"},{"key":"1425_CR96","doi-asserted-by":"publisher","first-page":"1214301","DOI":"10.3389\/fnins.2023.1214301","volume":"17","author":"S He","year":"2023","unstructured":"He S, Liang Q, Zhu J, Wang C, Lin X, Wu D, et al. Research landscape and emerging trends of diabetes-associated cognitive dysfunction: a bibliometric analysis. Front Neurosci. 2023;17:1214301.","journal-title":"Front Neurosci"},{"key":"1425_CR97","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","volume":"333","author":"P Sa-Nguanmoo","year":"2017","unstructured":"Sa-Nguanmoo P, Tanajak P, Kerdphoo S, Jaiwongkam T, Pratchayasakul W, Chattipakorn N, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017;333:43\u201350.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"1425_CR98","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3390\/neurolint16060124","volume":"16","author":"CH Hung","year":"2024","unstructured":"Hung CH, Lu LY. New insights into the role of SGLT-2 inhibitors in the prevention of dementia. Neurol Int. 2024;16(6):1717\u201330.","journal-title":"Neurol Int"},{"issue":"2","key":"1425_CR99","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2337\/dc22-1705","volume":"46","author":"CY Wu","year":"2023","unstructured":"Wu CY, Iskander C, Wang C, Xiong LY, Shah BR, Edwards JD, et al. Association of Sodium-Glucose cotransporter 2 inhibitors with time to dementia: A Population-Based cohort study. Diabetes Care. 2023;46(2):297\u2013304.","journal-title":"Diabetes Care"},{"key":"1425_CR100","doi-asserted-by":"publisher","first-page":"101131","DOI":"10.1016\/j.yfrne.2024.101131","volume":"73","author":"YJ Youn","year":"2024","unstructured":"Youn YJ, Kim S, Jeong HJ, Ah YM, Yu YM. Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis. Front Neuroendocrinol. 2024;73:101131.","journal-title":"Front Neuroendocrinol"},{"issue":"10","key":"1425_CR101","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.7326\/M23-3220","volume":"177","author":"B Hong","year":"2024","unstructured":"Hong B, Bea S, Ko HY, Kim WJ, Cho YM, Shin JY. Sodium-Glucose Cotransporter-2 inhibitors, dulaglutide, and risk for dementia: A Population-Based cohort study. Ann Intern Med. 2024;177(10):1319\u201329.","journal-title":"Ann Intern Med"},{"issue":"21","key":"1425_CR102","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"1425_CR103","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"16","key":"1425_CR104","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01425-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-025-01425-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01425-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T15:03:15Z","timestamp":1748098995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-025-01425-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1007\/s11910-025-01425-7","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"8 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"37"}}